Search Results - "Kleiman, N. S."

Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy by Roffi, M., Chew, D.P., Mukherjee, D., Bhatt, D.L., White, J.A., Moliterno, D.J., Heeschen, C., Hamm, C.W., Robbins, M.A., Kleiman, N.S., Théroux, P., White, H.D., Topol, E.J.

“…Aims To assess the efficacy of platelet glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes primarily medically managed. Methods and…”
Get full text

Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials by Gurm, H S, Bhatt, D L, Lincoff, A M, Tcheng, J E, Kereiakes, D J, Kleiman, N S, Jia, G, Topol, E J

“…Background: Raised inflammatory markers are associated with worse outcome after percutaneous coronary interventions (PCI). An increase in the white blood cell…”
Get full text

Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors by Kleiman, Neal S.

“…Antagonists of the platelet receptor glycoprotein (GP) IIb-IIIa are a novel class of antithrombotic agents that provide more comprehensive platelet blockade…”
Get full text

Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus : Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) diabetic substudy by MARSO, S. P, LINCOFF, A. M, ELLIS, S. G, BHATT, D. L, TANGUAY, J.-F, KLEIMAN, N. S, HAMMOUD, T, BOOTH, J. E, SAPP, S. K, TOPOL, E. J

“…Stenting likely decreases the need for target-vessel revascularization procedures in diabetic patients compared with balloon angioplasty. However, the efficacy…”
Get full text

Platelet glycoprotein IIb/IIIa antagonists : What are the relevant issues concerning their pharmacology and clinical use? by SCARBOROUGH, R. M, KLEIMAN, N. S, PHILLIPS, D. R

“…During the last decade, intensive efforts have been made to evaluate the role of the platelet glycoprotein (GP) IIb/IIIa complex in platelet-mediated thrombus…”
Get full text

Myonecrosis After Revascularization Procedures by Califf, Robert M., Abdelmeguid, Alaa E., Kuntz, Richard E., Popma, Jeffrey J., Davidson, Charles J., Cohen, Eric A., Kleiman, Neal S., Mahaffey, Kenneth W., Topol, Eric J., Pepine, Carl J., Lipicky, Ray J., Granger, Christopher B., Harrington, Robert A., Tardiff, Barbara E., Crenshaw, Brian S., Bauman, Robert P., Zuckerman, Bram D., Chaitman, Bernard R., Bittl, John A., Ohman, E.Magnus

“…The detection of elevated cardiac enzyme levels and the occurrence of electrocardiographic (ECG) abnormalities after revascularization procedures have been the…”
Get full text

Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients by Reardon, Michael J, Van Mieghem, Nicolas M, Popma, Jeffrey J, Kleiman, Neal S, Søndergaard, Lars, Mumtaz, Mubashir, Adams, David H, Deeb, G. Michael, Maini, Brijeshwar, Gada, Hemal, Chetcuti, Stanley, Gleason, Thomas, Heiser, John, Lange, Rüdiger, Merhi, William, Oh, Jae K, Olsen, Peter S, Piazza, Nicolo, Williams, Mathew, Windecker, Stephan, Yakubov, Steven J, Grube, Eberhard, Makkar, Raj, Lee, Joon S, Conte, John, Vang, Eric, Nguyen, Hang, Chang, Yanping, Mugglin, Andrew S, Serruys, Patrick W.J.C, Kappetein, Arie P

“…Among patients at intermediate risk for aortic-valve surgery, transcatheter aortic-valve replacement (TAVR) was noninferior to standard surgery, although each…”
Get full text

Dobutamine echocardiography in myocardial hibernation : optimal dose and accuracy in predicting recovery of ventricular function after coronary angioplasty by AFRIDI, I, KLEIMAN, N. S, RAIZNER, A. E, ZOGHBI, W. A

“…Myocardial hibernation is a condition of chronic left ventricular dysfunction associated with severe coronary artery disease whereby significant recovery of…”
Get full text

Reticulated platelets and uninhibited COX‐1 and COX‐2 decrease the antiplatelet effects of aspirin by GUTHIKONDA, S., LEV, E. I., PATEL, R., DELAO, T., BERGERON, A. L., DONG, J.‐F., KLEIMAN, N. S.

“…Background: The mechanisms for the variability in antiplatelet effects of aspirin are unclear. Immature (reticulated) platelets may modulate the antiplatelet…”
Get full text

Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy by LAKKIS, N. M, NAGUEH, S. F, KLEIMAN, N. S, KILLIP, D, HE, Z.-X, VERANI, M. S, ROBERTS, R, SPENCER, W. H. S. III

“…Left ventricular outflow tract (LVOT) obstruction is frequently responsible for symptoms in hypertrophic obstructive cardiomyopathy (HOCM). Medical therapy is…”
Get full text

Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial Ischemia by Ohman, E. Magnus, Armstrong, Paul W, Christenson, Robert H, Granger, Christopher B, Katus, Hugo A, Hamm, Christian W, O'Hanesian, Mary Ann, Wagner, Galen S, Kleiman, Neal S, Harrell, Frank E, Califf, Robert M, Topol, Eric J, Lee, Kerry L

“…Patients who come to the hospital with acute myocardial ischemic syndromes represent a continuum of disease from unstable angina to acute infarction. The…”
Get full text

The declining prevalence of ST elevation myocardial infarction in patients presenting with acute coronary syndromes by Kleiman, N S, White, H D

“…The management of patients with acute coronary syndromes may be about to undergo a dramatic change…”
Get full text

First experience with direct, selective factor Xa inhibition in patients with non‐ST‐elevation acute coronary syndromes: results of the XaNADU‐ACS Trial by ALEXANDER, J. H., YANG, H., BECKER, R. C., KODAMA, K., GOODMAN, S., DYKE, C. K., KLEIMAN, N. S., HOCHMAN, J. S., BERGER, P. B., COHEN, E. A., LINCOFF, A. M., BURTON, J. R., BOVILL, E. G., KAWAI, C., ARMSTRONG, P. W., HARRINGTON, R. A.

“…Background: Unfractionated heparin is widely used in patients with non‐ST‐elevation acute coronary syndromes but has important limitations. Anticoagulants with…”
Get full text

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty by Tcheng, J E, Ellis, S G, George, B S, Kereiakes, D J, Kleiman, N S, Talley, J D, Wang, A L, Weisman, H F, Califf, R M, Topol, E J

“…Thrombosis has been implicated as central to the clinical complications of coronary angioplasty (PTCA). Chimeric monoclonal 7E3 Fab (c7E3 Fab) is the first of…”
Get full text

Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes by Bhatt, Deepak L., Peterson, Eric D., Harrington, Robert A., Ou, Fang-Shu, Cannon, Christopher P., Gibson, C. Michael, Kleiman, Neal S., Brindis, Ralph G., Peacock, W. Frank, Brener, Sorin J., Menon, Venu, Smith, Sidney C., Pollack, Charles V., Gibler, W. Brian, Ohman, E. Magnus, Roe, Matthew T.

“…Aims The presence of peripheral arterial disease (PAD) or cerebrovascular disease (CVD) is associated with higher likelihood of significant coronary artery…”
Get full text

Recombinant hirudin for unstable angina pectoris : a multicenter, randomized angiographic trial by TOPOL, E. J, FUSTER, V, RAO, A. K, DEBOWEY, D, SCHWARTZ, D, HENIS, M, CHESEBRO, J, HARRINGTON, R. A, CALIFF, R. M, KLEIMAN, N. S, KEREIAKES, D. J, COHEN, M, CHAPEKIS, A, GOLD, H. K, TANNENBAUM, M. A

“…Coronary artery thrombosis plays an important pathophysiological role in unstable angina and non-Q-wave myocardial infarction. To date, heparin and…”
Get full text

Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty by Kereiakes, J., Kleiman, Neal S., Ambrose, John, Cohen, Marc, Rodriguez, Samuel, Palabrica, Theresa, Herrmann, Howard C., Sutton, Joseph M., Weaver, W.Douglas, McKee, Donna B., Fitzpatrick, Virginia, Sax, Frederic L.

“…Objectives. The objectives of this double-blind, placebo-controlled, randomized dose-ranging study were 1) to examine the safety and tolerability of tirofiban…”
Get full text

Initial experience with factor‐Xa inhibition in percutaneous coronary intervention: the XaNADU‐PCI Pilot by Alexander, J. H., Dyke, C. K., Yang, H., Becker, R. C., Hasselblad, V., Zillman, L. A., Kleiman, N. S., Hochman, J. S., Berger, P. B., Cohen, E. A., Lincoff, A. M., Saint‐Jacques, H., Chetcuti, S., Burton, J. R., Buergler, J. M., Spence, F. P., Shimoto, Y., Robertson, T. L., Kunitada, S., Bovill, E. G., Armstrong, P. W., Harrington, R. A.

“…Background: Direct factor (F)Xa inhibition is an attractive method to limit thrombotic complications during percutaneous coronary intervention (PCI)…”
Get full text

Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors by Kleiman, Neal S., Raizner, Albert E., Jordan, Robert, Wang, Ann L., Norton, Daniel, Mace, Kenneth F., Joshi, Alaknanda, Coller, Barry S., Weisman, Harlan F.

“…This study sought to describe in detail the pharmacokinetics and pharmacodynamics of chimeric monoclonal 7E3 Fab (c7E3 Fab) and to compare platelet responses…”
Get full text

Intensive medical therapy versus coronary angioplasty for suppression of myocardial ischemia in survivors of acute myocardial infarction: A prospective, randomized pilot study by DAKIK, H. A, KLEIMAN, N. S, FARMER, J. A, HE, Z.-X, WENDT, J. A, PRATT, C. M, VERANI, M. S, MAHMARIAN, J. J

“…Patients who have inducible ischemia after acute myocardial infarction (AMI) generally undergo coronary angiography with the intent to revascularize. Whether…”
Get full text